Compare BIRK & BLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BIRK | BLCO |
|---|---|---|
| Founded | 1774 | 1853 |
| Country | United Kingdom | Canada |
| Employees | N/A | N/A |
| Industry | | Ophthalmic Goods |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5B | 6.1B |
| IPO Year | 2023 | 2022 |
| Metric | BIRK | BLCO |
|---|---|---|
| Price | $34.32 | $16.64 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 23 | 15 |
| Target Price | ★ $50.32 | $19.39 |
| AVG Volume (30 Days) | ★ 1.7M | 472.7K |
| Earning Date | 08-13-2026 | 10-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $5,101,000,000.00 |
| Revenue This Year | $11.98 | $7.68 |
| Revenue Next Year | $13.81 | $5.95 |
| P/E Ratio | $17.48 | ★ N/A |
| Revenue Growth | N/A | ★ 6.47 |
| 52 Week Low | $29.93 | $14.44 |
| 52 Week High | $50.73 | $18.92 |
| Indicator | BIRK | BLCO |
|---|---|---|
| Relative Strength Index (RSI) | 52.80 | 45.01 |
| Support Level | $33.06 | $15.89 |
| Resistance Level | $37.29 | $16.58 |
| Average True Range (ATR) | 1.07 | 0.47 |
| MACD | 0.34 | -0.07 |
| Stochastic Oscillator | 45.21 | 52.22 |
Birkenstock is a German footwear brand known for comfort-focused, timeless designs, with 76% of 2022 sales coming from its top five iconic models. Products are made in Europe using sustainable, mostly locally sourced materials. The brand combines orthopedic function with everyday style, appealing to a broad audience. The Americas account for 52% of sales, EMEA 37%, with the remainder coming from Asia-Pacific, which has also the higher future growth expectations.
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.